Inspyr Therapeutics, Inc. Announces Resignation of Michael Cain as Chief Executive Officer
June 21, 2021 at 09:17 am EDT
Share
On June 16, 2021, the Inspyr Therapeutics, Inc. was informed by Michael Cain, that he is resigning as chief executive officer of the Company. Mr. Cain’s resignation did not result from any disagreement with the Company on any matter relating to its operations, policies, or practices.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
